Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

SynAct Pharma

20.55 SEK

+0.49 %

Less than 1K followers

SYNACT

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+0.49 %
-10.26 %
+8.04 %
+9.78 %
+129.22 %
+82.55 %
-67.60 %
-41.31 %
+345.81 %

SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.

Read more
Market cap
1.1B SEK
Turnover
859.91K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
18.2.
2026

Annual report '25

All
Webcasts
Press releases
3rd party
ShowingAll content types
Regulatory press release11/27/2025, 10:15 AM

Report from the Extraordinary General Meeting of SynAct Pharma AB

SynAct Pharma
Press release11/19/2025, 7:34 AM

BioStock: Video from SynAct Pharma's presentation at BioStock Life Science Summit 2025

SynAct Pharma
Press release11/19/2025, 6:30 AM

SynAct Participating at Redeye Autoimmune and Inflammatory Diseases event on November 19th

SynAct Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Third party research11/6/2025, 9:37 AM

Synact Pharma: Differentiated inflammation resolution approach - Edison

SynAct Pharma is focused on inflammation resolution therapeutics. Its lead asset, resomelagon, is differentiated by its novel mechanism, targeting specific melanocortin receptor subtypes believed to have direct effects on the immune system. The main ...

SynAct Pharma
Press release11/3/2025, 7:00 AM

Resomelagon Phase-2B ADVANCE Study Update: 190 Patients Randomized Tracking for Year-End Recruitment Completion

SynAct Pharma
Press release10/31/2025, 10:44 AM

Redeye: SynAct (Q3 Update) - ADVANCE Approaching Full Recruitment

SynAct Pharma
Press release10/31/2025, 10:43 AM

BioStock: SynAct advances pipeline and extends runway to 2027

SynAct Pharma
Press release10/31/2025, 7:00 AM

SynAct Pharma Participating in Partnering and Investor Conference Bio-Europe® 2025

SynAct Pharma
Regulatory press release10/30/2025, 6:30 AM

SynAct Pharma publishes Q3 2025 interim results

SynAct Pharma
Regulatory press release10/29/2025, 5:30 PM

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF SYNACT PHARMA AB

SynAct Pharma
Press release10/28/2025, 9:50 AM

Edison Investment Research Ltd. Initiates Coverage of SynAct Pharma

SynAct Pharma
Press release10/10/2025, 11:00 AM

BioStock: SynAct Pharma's CBO: “We are pioneering the future of inflammation care”

SynAct Pharma
Press release10/8/2025, 6:05 AM

BioStock: SynAct Pharma: "We're on track and on time"

SynAct Pharma
Regulatory press release9/29/2025, 5:45 AM

Proposal for a resolution on authorization for the Board of Directors to resolve on acquisition and transfer of own shares

SynAct Pharma
Press release9/25/2025, 5:30 AM

SynAct Pharma to Participate in Nordic Life Science Days 2025

SynAct Pharma
Regulatory press release9/16/2025, 6:45 AM

SynAct Pharma’s CFO Björn Westberg leaves for new leading position

SynAct Pharma
Press release9/8/2025, 5:00 AM

SynAct Pharma AB - Notification of Warrant and Share Transactions by Hunter Capital AB and Heights Capital Management

SynAct Pharma
Press release9/5/2025, 5:50 AM

SynAct appoints Mads Bjerregaard as Chief Business Officer

SynAct Pharma
Regulatory press release8/29/2025, 4:00 PM

Change in number of shares and votes in SynAct Pharma AB

SynAct Pharma
Press release8/21/2025, 3:10 PM

BioStock: SynAct Pharma strengthens strategy and financials in Q2

SynAct Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.